With the advent of 64-slice CT, coronary CT angiography (CCTA) exams of low-risk patients presenting to the emergency department with chest pain are feasible given the nearly 100 percent negative predictive value of the test, according to a scientific statement from the American Heart Association (AHA) published in the Aug. 17 issue of Circulation.
The use of fractional-flow reserve (FFR) resulted in significantly lower PCIs compared with intravascular ultrasound (IVUS) in patients with intermediate coronary artery disease (CAD), based on study results in this month's Journal of the American College of Cardiology: Cardiovascular Interventions.
The addition of Molecular Insight Pharmaceuticals’ Zemiva imaging data to initially available clinical information contributes to the early diagnosis and evaluation of myocardial ischemia and acute coronary syndrome, according to a Phase 2 clinical trial published in the July 20 edition of the Journal of the American College of Cardiology (JACC).
Imaging with stress cardiac MRI in an observation unit can reduce incident cost without missing acute coronary syndrome in patients with emergent chest pain when compared to inpatient care, according to a study published online May 31 in the Annals of Emergency Medicine.
Written by Justine Cadet
Slightly more than one-third of patients without known disease, who underwent elective cardiac catheterization, had obstructive coronary artery disease (CAD) out of nearly 400,000 patients at 663 sites, based on study findings published March 11 in the New England Journal of Medicine. However, in an interview, Timothy D. Henry, MD, from Minneapolis Heart Institute, said that when reviewing the study’s data in its entirety, it appears that most practices are performing these procedures properly.
Written by Justine Cadet
With the plethora of clinical data emerging at this month’s American College of Cardiology annual meeting, the sessions are seeking to provide clinicians and administrators with methods to improve the quality of evidence-based care.
The U.S. Patent and Trademark Office (USPTA) has granted a notice of allowance to cardiac diagnostic technology provider NewCardio for its urgent care solution Cardio3KG.
A majority of patients (61 percent) evaluated for chest pain of uncertain cardiac cause have a coronary artery calcium (CAC) score of zero, which predicts both a normal SPECT result and an excellent short-term outcome, according to a single-center study published online Feb. 8 in the Annals of Emergency Medicine.
SAN FRANCISCO—In PROSPECT, the first prospective, natural history trial of atherosclerosis using multimodality imaging to characterize the coronary tree, researchers found that about 20 percent of patients with acute coronary syndromes successfully treated with stents and medical therapy develop at least one major coronary event within three years, with adverse events equally attributable to recurrence at originally treated culprit lesions and to previously untreated non-culprit coronary segments.
Ultrasound can be used to determine a patient's cardaic event risk after a transient ischemic attack (TIA). An evaluation of transcranial and extracranial Doppler ultrasonography, published July 30 in BMC Medical Imaging, demonstrated that both future stroke and future cardiovascular ischemic events can be predicted by abnormal findings.
Patients demonstrating positively remodeled coronary segments with low-attenuation plaques on CT angiography (CTA) were at a higher risk of acute coronary syndrome developing over time when compared with patients having lesions without these characteristics, according to a study in the July 30 issue in the Journal in the American College of Cardiology.
The Appropriate Use Criteria (AUC) task force has released the AUC for Cardiac Radionuclide Imaging, which refines appropriate use of pharmacologic tests compared with exercise stress tests and updates recommendations regarding radionuclide imaging in the perioperative setting.
Fifty percent of patients with acute chest pain and low-to-intermediate likelihood of acute coronary syndrome (ACS) were free of coronary artery disease by CT and had no ACS, according to ROMICAT trial results published in the May 5 issue of the Journal of the American College of Cardiology.
Zemiva, a molecular imaging radiopharmaceutical, in combination with initial clinical information in patients suspected of acute coronary syndrome (ACS), resulted in significantly improved sensitivity compared to the sensitivity of the initial clinical diagnosis alone, while maintaining specificity, according to a Phase 2 trial sponsored by manufacturer Molecular Insight Pharmaceuticals.
|